Raymond James & Associates Buys 74,829 Shares of Intuitive Surgical, Inc. (NASDAQ:ISRG)

Raymond James & Associates lifted its stake in shares of Intuitive Surgical, Inc. (NASDAQ:ISRG) by 29.8% in the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 326,295 shares of the medical equipment provider’s stock after acquiring an additional 74,829 shares during the period. Raymond James & Associates owned approximately 0.09% of Intuitive Surgical worth $130,221,000 at the end of the most recent quarter.

Other large investors also recently made changes to their positions in the company. Norges Bank bought a new position in shares of Intuitive Surgical in the 4th quarter valued at about $1,313,238,000. WCM Investment Management LLC bought a new position in shares of Intuitive Surgical in the 4th quarter valued at about $575,536,000. International Assets Investment Management LLC grew its position in shares of Intuitive Surgical by 32,360.5% in the 4th quarter. International Assets Investment Management LLC now owns 686,865 shares of the medical equipment provider’s stock valued at $231,721,000 after acquiring an additional 684,749 shares during the period. Alphinity Investment Management Pty Ltd grew its position in shares of Intuitive Surgical by 113.2% in the 4th quarter. Alphinity Investment Management Pty Ltd now owns 1,276,158 shares of the medical equipment provider’s stock valued at $430,525,000 after acquiring an additional 677,455 shares during the period. Finally, J.P. Morgan Private Wealth Advisors LLC bought a new position in shares of Intuitive Surgical in the 3rd quarter valued at about $178,667,000. Institutional investors own 83.64% of the company’s stock.

Insider Activity at Intuitive Surgical

In other Intuitive Surgical news, SVP Mark Brosius sold 196 shares of the company’s stock in a transaction on Tuesday, March 5th. The shares were sold at an average price of $400.00, for a total transaction of $78,400.00. Following the transaction, the senior vice president now owns 1,842 shares in the company, valued at $736,800. The transaction was disclosed in a filing with the SEC, which is accessible through this link. In other Intuitive Surgical news, EVP Robert Desantis sold 20,296 shares of the company’s stock in a transaction on Friday, March 8th. The shares were sold at an average price of $393.80, for a total transaction of $7,992,564.80. Following the transaction, the executive vice president now owns 5,507 shares in the company, valued at $2,168,656.60. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, SVP Mark Brosius sold 196 shares of the company’s stock in a transaction on Tuesday, March 5th. The stock was sold at an average price of $400.00, for a total transaction of $78,400.00. Following the transaction, the senior vice president now owns 1,842 shares in the company, valued at approximately $736,800. The disclosure for this sale can be found here. Insiders have sold 226,967 shares of company stock worth $87,848,586 in the last quarter. Company insiders own 0.80% of the company’s stock.

Intuitive Surgical Stock Performance

Shares of NASDAQ ISRG traded down $3.52 during midday trading on Tuesday, reaching $370.62. The stock had a trading volume of 1,212,524 shares, compared to its average volume of 1,644,877. Intuitive Surgical, Inc. has a twelve month low of $254.85 and a twelve month high of $403.76. The company’s 50 day moving average price is $385.96 and its 200 day moving average price is $348.19. The firm has a market cap of $131.46 billion, a price-to-earnings ratio of 66.90, a price-to-earnings-growth ratio of 4.85 and a beta of 1.36.

Intuitive Surgical (NASDAQ:ISRG) last released its earnings results on Thursday, April 18th. The medical equipment provider reported $1.50 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.40 by $0.10. Intuitive Surgical had a net margin of 27.16% and a return on equity of 12.91%. The company had revenue of $1.89 billion for the quarter, compared to the consensus estimate of $1.87 billion. During the same quarter in the previous year, the company earned $1.00 EPS. Intuitive Surgical’s quarterly revenue was up 11.5% compared to the same quarter last year. Equities analysts forecast that Intuitive Surgical, Inc. will post 4.8 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of research analysts have recently commented on the stock. Raymond James lifted their price objective on shares of Intuitive Surgical from $372.00 to $435.00 and gave the company an “outperform” rating in a research report on Thursday, January 25th. Royal Bank of Canada raised their target price on shares of Intuitive Surgical from $400.00 to $432.00 and gave the stock an “outperform” rating in a research note on Wednesday, January 24th. Citigroup raised their target price on shares of Intuitive Surgical from $428.00 to $462.00 and gave the stock a “buy” rating in a research note on Wednesday, April 3rd. Piper Sandler raised their target price on shares of Intuitive Surgical from $425.00 to $435.00 and gave the stock an “overweight” rating in a research note on Friday, April 19th. Finally, Mizuho raised their target price on shares of Intuitive Surgical from $350.00 to $390.00 and gave the stock a “neutral” rating in a research note on Thursday, January 25th. Five analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the stock. Based on data from MarketBeat.com, Intuitive Surgical currently has an average rating of “Moderate Buy” and an average target price of $396.17.

Intuitive Surgical Company Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.